skip to main content
Idioma:
Refinado por: Nome da Publicação: The Lancet remover idioma: Russo remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Bissler, John J, Prof ; Kingswood, J Christopher, FRCP ; Radzikowska, Elżbieta, MD ; Zonnenberg, Bernard A, MD ; Frost, Michael, MD ; Belousova, Elena, Prof ; Sauter, Matthias, MD ; Nonomura, Norio, Prof ; Brakemeier, Susanne, MD ; de Vries, Petrus J, Prof ; Whittemore, Vicky H, PhD ; Chen, David, PhD ; Sahmoud, Tarek, MD ; Shah, Gaurav, MD ; Lincy, Jeremie, MS ; Lebwohl, David, MD ; Budde, Klemens, Prof

The Lancet (British edition), 2013-03, Vol.381 (9869), p.817-824 [Periódico revisado por pares]

Kidlington: Elsevier

Texto completo disponível

Citações Citado por
2
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Fuchs, Charles S, Dr Prof ; Tomasek, Jiri, MD ; Yong, Cho Jae, Prof ; Dumitru, Filip, MD ; Passalacqua, Rodolfo, MD ; Goswami, Chanchal, Prof ; Safran, Howard, Prof ; dos Santos, Lucas Vieira, MD ; Aprile, Giuseppe, MD ; Ferry, David R, Prof ; Melichar, Bohuslav, Prof ; Tehfe, Mustapha, MD ; Topuzov, Eldar, Prof ; Zalcberg, John Raymond, Prof ; Chau, Ian, MD ; Campbell, William, Prof ; Sivanandan, Choondal, MD ; Pikiel, Joanna, MD ; Koshiji, Minori, MD ; Hsu, Yanzhi, PhD ; Liepa, Astra M, PharmD ; Gao, Ling, PhD ; Schwartz, Jonathan D, MD ; Tabernero, Josep, MD

The Lancet (British edition), 2014-01, Vol.383 (9911), p.31-39 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Jacobson, Ira M, Prof ; Dore, Gregory J, Prof ; Foster, Graham R, Prof ; Fried, Michael W, Prof ; Radu, Monica, MD ; Rafalsky, Vladimir V, Prof ; Moroz, Larysa, Prof ; Craxi, Antonio, Prof ; Peeters, Monika, MSc ; Lenz, Oliver, PhD ; Ouwerkerk-Mahadevan, Sivi, PhD ; De La Rosa, Guy, MD ; Kalmeijer, Ronald, MD ; Scott, Jane, PhD ; Sinha, Rekha, PhD ; Beumont-Mauviel, Maria, PhD

The Lancet (British edition), 2014-08, Vol.384 (9941), p.403-413 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

Franz, David Neal, Prof ; Belousova, Elena, MD ; Sparagana, Steven, MD ; Bebin, E Martina, MD ; Frost, Michael, MD ; Kuperman, Rachel, MD ; Witt, Olaf, MD ; Kohrman, Michael H, MD ; Flamini, J Robert, MD ; Wu, Joyce Y, MD ; Curatolo, Paolo, Prof ; de Vries, Petrus J, Prof ; Whittemore, Vicky H, PhD ; Thiele, Elizabeth A, MD ; Ford, James P, MS ; Shah, Gaurav, MD ; Cauwel, Helene, MSc ; Lebwohl, David, MD ; Sahmoud, Tarek, MD ; Jozwiak, Sergiusz, MD

The Lancet (British edition), 2013-01, Vol.381 (9861), p.125-132 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Navarra, Sandra V, MD ; Guzmán, Renato M, MD ; Gallacher, Alberto E, MD ; Hall, Stephen, MD ; Levy, Roger A, MD ; Jimenez, Renato E, MD ; Li, Edmund K-M, MD ; Thomas, Mathew, MD ; Kim, Ho-Youn, MD ; León, Manuel G, MD ; Tanasescu, Coman, MD ; Nasonov, Eugeny, MD ; Lan, Joung-Liang, MD ; Pineda, Lilia, MD ; Zhong, Z John, PhD ; Freimuth, William, MD ; Petri, Michelle A, MD

The Lancet (British edition), 2011, Vol.377 (9767), p.721-731 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Cortes, Javier, MD ; O'Shaughnessy, Joyce, MD ; Loesch, David, MD ; Blum, Joanne L, MD ; Vahdat, Linda T, MD ; Petrakova, Katarina, MD ; Chollet, Philippe, MD ; Manikas, Alexey, MD ; Diéras, Veronique, MD ; Delozier, Thierry, MD ; Vladimirov, Vladimir, MD ; Cardoso, Fatima, MD ; Koh, Han, MD ; Bougnoux, Philippe, MD ; Dutcus, Corina E, MD ; Seegobin, Seth, MSc ; Mir, Denis, MSc ; Meneses, Nicole, MSHS ; Wanders, Jantien, MD ; Twelves, Chris, Prof

The Lancet (British edition), 2011-03, Vol.377 (9769), p.914-923 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Material Type:
Artigo 		Adicionar ao Meu Espaço

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Gianni, Luca, Dr ; Eiermann, Wolfgang, MD ; Semiglazov, Vladimir, MD ; Manikhas, Alexey, MD ; Lluch, Ana, MD ; Tjulandin, Sergey, MD ; Zambetti, Milvia, MD ; Vazquez, Federico, MD ; Byakhow, Mikhail, MD ; Lichinitser, Mikhail, MD ; Climent, Miguel Angel, MD ; Ciruelos, Eva, MD ; Ojeda, Belén, MD ; Mansutti, Mauro, MD ; Bozhok, Alla, MD ; Baronio, Roberta, MSci ; Feyereislova, Andrea, MD ; Barton, Claire, MD ; Valagussa, Pinuccia ; Baselga, Jose, MD

The Lancet (British edition), 2010-01, Vol.375 (9712), p.377-384 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Baselga, José, Dr ; Bradbury, Ian, PhD ; Eidtmann, Holger, MD ; Di Cosimo, Serena, MD ; de Azambuja, Evandro, MD ; Aura, Claudia, MD ; Gómez, Henry, MD ; Dinh, Phuong, MD ; Fauria, Karine, PhD ; Van Dooren, Veerle, MSc ; Aktan, Gursel, MD ; Goldhirsch, Aron, MD ; Chang, Tsai-Wang, MD ; Horváth, Zsolt, MD ; Coccia-Portugal, Maria, MD ; Domont, Julien, MD ; Tseng, Ling-Min, MD ; Kunz, Georg, MD ; Sohn, Joo Hyuk, MD ; Semiglazov, Vladimir, MD ; Lerzo, Guillermo, MD ; Palacova, Marketa, MD ; Probachai, Volodymyr, MD ; Pusztai, Lajos, DPhil ; Untch, Michael, PhD ; Gelber, Richard D, PhD ; Piccart-Gebhart, Martine, PhD

The Lancet (British edition), 2012-02, Vol.379 (9816), p.633-640 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

Smolen, Josef S, Prof ; Nash, Peter, MD ; Durez, Patrick, Prof ; Hall, Stephen, MD ; Ilivanova, Elena, MD ; Irazoque-Palazuelos, Fedra, MD ; Miranda, Pedro, MD ; Park, Min-Chan, MD ; Pavelka, Karel, Prof ; Pedersen, Ronald, MS ; Szumski, Annette, MS ; Hammond, Constance, BS ; Koenig, Andrew S, DO ; Vlahos, Bonnie, BSN

The Lancet (British edition), 2013-03, Vol.381 (9870), p.918-929 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial

Mega, JL, MD ; Braunwald, E, Prof ; Mohanavelu, S, MS ; Burton, P, MD ; Poulter, R, MB ; Misselwitz, F, MD ; Hricak, V, Prof ; Barnathan, ES, MD ; Bordes, P, MD ; Witkowski, A, Prof ; Markov, V, Prof ; Oppenheimer, L, PhD ; Gibson, CM, MD

The Lancet (British edition), 2009-07, Vol.374 (9683), p.29-38 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.